These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
175 related items for PubMed ID: 9375899
1. Treatment of Paget's disease of bone with intravenous pamidronate: comparison of 2 different modes of treatment. Ismail AA, Fox P, Stamp TC, Dhillon V, Crisp AJ, MacGregor A. J Rheumatol; 1997 Nov; 24(11):2266-7. PubMed ID: 9375899 [No Abstract] [Full Text] [Related]
2. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH. Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907 [Abstract] [Full Text] [Related]
3. Determinants of remission of Paget's disease of bone. Patel S, Stone MD, Coupland C, Hosking DJ. J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048 [Abstract] [Full Text] [Related]
6. Pamidronate infusions for the treatment of Paget's disease of bone. Mazieres B, Ahmed I, Moulinier L, Bon E, Cantagrel A, Laroche M. Rev Rhum Engl Ed; 1996 Jan; 63(1):36-43. PubMed ID: 9064108 [Abstract] [Full Text] [Related]
9. Paget's disease of bone: presentation, extent and response to bisphosphonates. Wang LM, Au-Yeong ML, McKenna MJ. Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502 [Abstract] [Full Text] [Related]
11. Response of biochemical markers of bone turnover to pamidronate infusion in Paget's disease of bone. Sharp CA, Worsfold M, Rowlands PR, Davie MW. Semin Arthritis Rheum; 1994 Feb; 23(4):242-3. PubMed ID: 8009239 [No Abstract] [Full Text] [Related]
12. Bisphosphonate resistance in Paget's disease of bone. Joshua F, Epstein M, Major G. Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487 [Abstract] [Full Text] [Related]
15. Intravenous pamidronate in Paget's disease--response is dependent on radiographic and biochemical severity. Stuckey BG, Gutteridge DH, Stewart GO, Prince RL, Ward LC, Kent GN, Prince RI, Retallack RW, Bhagat CI, Nicholson GC. Semin Arthritis Rheum; 1994 Feb; 23(4):286. PubMed ID: 8009263 [No Abstract] [Full Text] [Related]
16. Use of the bisphosphonate space in treatment and retreatment of Paget's disease. Stone MD, Patel S, Hosking DJ. Semin Arthritis Rheum; 1994 Feb; 23(4):278. PubMed ID: 8009256 [No Abstract] [Full Text] [Related]
19. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Abelson A. Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324 [Abstract] [Full Text] [Related]
20. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J. Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158 [Abstract] [Full Text] [Related] Page: [Next] [New Search]